Current drugs for HIV-1: from challenges to potential in HIV/AIDS
The human immunodeficiency virus (HIV) persists in latently infected CD4+T cells and integrates with the host genome until cell death. Acquired immunodeficiency syndrome (AIDS) is associated with HIV-1. Possibly, treating HIV/AIDS is an essential but challenging clinical goal. This review provides a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1294966/full |
| _version_ | 1797648923341357056 |
|---|---|
| author | Yuan Peng Yanjun Zong Dongfeng Wang Junbing Chen Junbing Chen Zhe-Sheng Chen Fujun Peng Zhijun Liu |
| author_facet | Yuan Peng Yanjun Zong Dongfeng Wang Junbing Chen Junbing Chen Zhe-Sheng Chen Fujun Peng Zhijun Liu |
| author_sort | Yuan Peng |
| collection | DOAJ |
| description | The human immunodeficiency virus (HIV) persists in latently infected CD4+T cells and integrates with the host genome until cell death. Acquired immunodeficiency syndrome (AIDS) is associated with HIV-1. Possibly, treating HIV/AIDS is an essential but challenging clinical goal. This review provides a detailed account of the types and mechanisms of monotherapy and combination therapy against HIV-1 and describes nanoparticle and hydrogel delivery systems. In particular, the recently developed capsid inhibitor (Lenacapavir) and the Ainuovirine/tenofovir disoproxil fumarate/lamivudine combination (ACC008) are described. It is interestingly to note that the lack of the multipass transmembrane proteins serine incorporator 3 (SERINC3) and the multipass transmembrane proteins serine incorporator 5 (SERINC5) may be one of the reasons for the enhanced infectivity of HIV-1. This discovery of SERINC3 and SERINC5 provides new ideas for HIV-1 medication development. Therefore, we believe that in treating AIDS, antiviral medications should be rationally selected for pre-exposure and post-exposure prophylaxis to avoid the emergence of drug resistance. Attention should be paid to the research and development of new drugs to predict HIV mutations as accurately as possible and to develop immune antibodies to provide multiple guarantees for the cure of AIDS. |
| first_indexed | 2024-03-11T15:39:01Z |
| format | Article |
| id | doaj.art-3c4f0fc05f4f437ca473d335e8d89a66 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-11T15:39:01Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-3c4f0fc05f4f437ca473d335e8d89a662023-10-26T12:13:07ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-10-011410.3389/fphar.2023.12949661294966Current drugs for HIV-1: from challenges to potential in HIV/AIDSYuan Peng0Yanjun Zong1Dongfeng Wang2Junbing Chen3Junbing Chen4Zhe-Sheng Chen5Fujun Peng6Zhijun Liu7School of Clinical Medicine, Weifang Medical University, Weifang, ChinaDepartment of Medical Microbiology, School of Basic Medical Sciences, Weifang Medical University, Weifang, ChinaSchool of Basic Medical Sciences, Weifang Medical University, Weifang, ChinaDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai, ChinaKey Laboratory of Carcinogenesis and Cancer Invasion, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York, NY, United StatesSchool of Basic Medical Sciences, Weifang Medical University, Weifang, ChinaDepartment of Medical Microbiology, School of Basic Medical Sciences, Weifang Medical University, Weifang, ChinaThe human immunodeficiency virus (HIV) persists in latently infected CD4+T cells and integrates with the host genome until cell death. Acquired immunodeficiency syndrome (AIDS) is associated with HIV-1. Possibly, treating HIV/AIDS is an essential but challenging clinical goal. This review provides a detailed account of the types and mechanisms of monotherapy and combination therapy against HIV-1 and describes nanoparticle and hydrogel delivery systems. In particular, the recently developed capsid inhibitor (Lenacapavir) and the Ainuovirine/tenofovir disoproxil fumarate/lamivudine combination (ACC008) are described. It is interestingly to note that the lack of the multipass transmembrane proteins serine incorporator 3 (SERINC3) and the multipass transmembrane proteins serine incorporator 5 (SERINC5) may be one of the reasons for the enhanced infectivity of HIV-1. This discovery of SERINC3 and SERINC5 provides new ideas for HIV-1 medication development. Therefore, we believe that in treating AIDS, antiviral medications should be rationally selected for pre-exposure and post-exposure prophylaxis to avoid the emergence of drug resistance. Attention should be paid to the research and development of new drugs to predict HIV mutations as accurately as possible and to develop immune antibodies to provide multiple guarantees for the cure of AIDS.https://www.frontiersin.org/articles/10.3389/fphar.2023.1294966/fullanti-HIV-1 drugsmonotherapycombination therapyHIV/AIDS treatmentpredict HIV mutationsSERINC3 |
| spellingShingle | Yuan Peng Yanjun Zong Dongfeng Wang Junbing Chen Junbing Chen Zhe-Sheng Chen Fujun Peng Zhijun Liu Current drugs for HIV-1: from challenges to potential in HIV/AIDS Frontiers in Pharmacology anti-HIV-1 drugs monotherapy combination therapy HIV/AIDS treatment predict HIV mutations SERINC3 |
| title | Current drugs for HIV-1: from challenges to potential in HIV/AIDS |
| title_full | Current drugs for HIV-1: from challenges to potential in HIV/AIDS |
| title_fullStr | Current drugs for HIV-1: from challenges to potential in HIV/AIDS |
| title_full_unstemmed | Current drugs for HIV-1: from challenges to potential in HIV/AIDS |
| title_short | Current drugs for HIV-1: from challenges to potential in HIV/AIDS |
| title_sort | current drugs for hiv 1 from challenges to potential in hiv aids |
| topic | anti-HIV-1 drugs monotherapy combination therapy HIV/AIDS treatment predict HIV mutations SERINC3 |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1294966/full |
| work_keys_str_mv | AT yuanpeng currentdrugsforhiv1fromchallengestopotentialinhivaids AT yanjunzong currentdrugsforhiv1fromchallengestopotentialinhivaids AT dongfengwang currentdrugsforhiv1fromchallengestopotentialinhivaids AT junbingchen currentdrugsforhiv1fromchallengestopotentialinhivaids AT junbingchen currentdrugsforhiv1fromchallengestopotentialinhivaids AT zheshengchen currentdrugsforhiv1fromchallengestopotentialinhivaids AT fujunpeng currentdrugsforhiv1fromchallengestopotentialinhivaids AT zhijunliu currentdrugsforhiv1fromchallengestopotentialinhivaids |